Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Gemcitabine Hydrochloride With or Without Bevacizumab in Treating Patients Who Are Undergoing Surgery for Pancreatic Cancer

This study has been withdrawn prior to enrollment.
Information provided by:
National Cancer Institute (NCI) Identifier:
First received: November 11, 2005
Last updated: April 27, 2015
Last verified: December 2006

RATIONALE: Drugs used in chemotherapy, such as gemcitabine hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells an help kill them or carry tumor-killing substances to them. Bevacizumab may also stop the growth of pancreatic cancer by blocking blood flow to the tumor. Giving gemcitabine hydrochloride together with bevacizumab after surgery may kill any remaining tumor cells.

PURPOSE: This phase II trial is studying gemcitabine hydrochloride and bevacizumab to see how well they work compared to gemcitabine hydrochloride alone in treating patients who are undergoing surgery for pancreatic cancer.

Condition Intervention Phase
Adenocarcinoma of the Pancreas
Recurrent Pancreatic Cancer
Stage I Pancreatic Cancer
Stage II Pancreatic Cancer
Stage III Pancreatic Cancer
Drug: bevacizumab
Drug: gemcitabine hydrochloride
Procedure: adjuvant therapy
Procedure: anti-cytokine therapy
Procedure: antiangiogenesis therapy
Procedure: antibody therapy
Procedure: biological therapy
Procedure: chemotherapy
Procedure: conventional surgery
Procedure: growth factor antagonist therapy
Procedure: monoclonal antibody therapy
Procedure: surgery
Phase 2

Study Type: Interventional
Study Design: Primary Purpose: Treatment
Official Title: Phase II Randomized Study of Surgical Resection and Adjuvant Gemcitabine Hydrochloride With Versus Without Bevacizumab in Patients With Adenocarcinoma of the Pancreas

Resource links provided by NLM:

Further study details as provided by National Cancer Institute (NCI):

Enrollment: 0
Detailed Description:



  • Compare the disease-free interval in patients with adenocarcinoma of the pancreas treated with surgical resection followed by adjuvant gemcitabine hydrochloride with vs without bevacizumab.


  • Compare overall survival in patients treated with these regimens.
  • Evaluate tumor gene expression profiles and levels of tumor angiogenesis markers to establish prognostic indicators for response in patients treated with these regimens.

OUTLINE: This is a randomized, controlled study.

All patients undergo surgical resection for the pancreatic tumor. Within 4-8 weeks after surgery, patients are stratified according to projected 2-year survival (≤ 5% vs > 5% and ≤ 33% vs > 33%). Patients are randomized to 1 of 2 treatment arms.

  • Arm I: Patients receive gemcitabine hydrochloride IV over 100 minutes on days 1, 8, and 15, and bevacizumab IV over 30-90 minutes on days 1 and 15. Treatment repeats every 28 days for 6 courses. Patients then receive bevacizumab IV alone every 2 weeks for up to 2 years in the absence of disease progression or unacceptable toxicity.
  • Arm II: Patients receive gemcitabine hydrochloride IV over 100 minutes on days 1, 8, and 15. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed periodically.

PROJECTED ACCRUAL: A total of 130 patients will be accrued for this study.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No


  • Histologically or cytologically confirmed adenocarcinoma of the pancreas
  • No evidence of distant metastasis on laparoscopy
  • No superior mesenteric artery or thrombosed superior mesenteric vein involvement
  • Superior mesenteric vein or portal vein involvement allowed
  • Evidence of a pancreatic mass by radiographic or endoscopic examination


Performance status

  • ECOG 0-1

Life expectancy

  • Not specified


  • WBC ≥ 2,500/mm^3
  • Absolute neutrophil count ≥ 1,250/mm^3
  • Platelet count ≥ 100,000/mm^3


  • Hepatitis B surface antigen negative
  • Hepatitis C virus negative
  • No history of hepatic cirrhosis


  • Creatinine ≤ 2.0 mg/dL
  • Proteinuria negative or trace by urinalysis OR
  • Protein < 1 g on 24 hr urine collection
  • No active gross hematuria


  • No severe congestive heart failure
  • No active ischemic heart disease
  • No ischemic changes on a cardiac thallium stress test
  • No uncontrolled hypertension (i.e., blood pressure ≤ 150/100 mm Hg despite antihypertensive therapy)
  • No active coagulation disorder


  • No active gross hemoptysis


  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception during the adjuvant therapy part of trial
  • HIV negative
  • No active infection
  • No wound healing problem from recent invasive procedure
  • No significant history of medical illness that would preclude patient from undergoing an operative procedure
  • No other malignancy requiring systemic therapy


Biologic therapy

  • Recovered from prior immunotherapy for pancreatic cancer
  • No prior bevacizumab


  • Recovered from prior chemotherapy for pancreatic cancer
  • No prior gemcitabine hydrochloride

Endocrine therapy

  • Recovered from prior hormonal therapy for pancreatic cancer


  • Recovered from prior radiotherapy for pancreatic cancer
  • No prior radiotherapy to the pancreas


  • No prior definitive resection of the primary pancreatic tumor
  • Prior surgery, other than resection of the primary tumor, allowed


  • More than 3 weeks since prior systemic therapy for this cancer
  • No concurrent therapeutic anticoagulation causing elevated PT or PTT
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00253526

Sponsors and Collaborators
National Cancer Institute (NCI)
Principal Investigator: Richard E. Royal, MD, FACS National Cancer Institute (NCI)
  More Information Identifier: NCT00253526     History of Changes
Obsolete Identifiers: NCT00158392
Other Study ID Numbers: CDR0000448825
Study First Received: November 11, 2005
Last Updated: April 27, 2015

Additional relevant MeSH terms:
Pancreatic Neoplasms
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Digestive System Neoplasms
Neoplasms by Site
Endocrine Gland Neoplasms
Digestive System Diseases
Pancreatic Diseases
Endocrine System Diseases
Antibodies, Monoclonal
Antimetabolites, Antineoplastic
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Antiviral Agents
Anti-Infective Agents
Enzyme Inhibitors
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Angiogenesis Inhibitors
Angiogenesis Modulating Agents processed this record on April 21, 2017